# Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis

> **NCT00555581** · PHASE2 · COMPLETED · sponsor: **Hospital for Special Surgery, New York** · enrollment: 30 (actual)

## Conditions studied

- Systemic Sclerosis

## Interventions

- **DRUG:** Imatinib Mesylate

## Key facts

- **NCT ID:** NCT00555581
- **Lead sponsor:** Hospital for Special Surgery, New York
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00555581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00555581, "Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00555581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*